TRIPLE NEGATIVE BREAST CANCER (TNBC), EARLY SETTING
Clinical trials for TRIPLE NEGATIVE BREAST CANCER (TNBC), EARLY SETTING explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST CANCER (TNBC), EARLY SETTING trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC), EARLY SETTING, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for High-Risk breast cancer: immune booster after chemo may keep cancer away
Disease control Not yet recruitingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard post-surgery treatment can prevent breast cancer from returning in people with early-stage triple-negative breast cancer who still had cancer after initial chemo and pembrolizumab. About 1000…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC), EARLY SETTING
Phase: PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated May 17, 2026 07:25 UTC
-
Gut check: could your microbiome predict cancer treatment success?
Knowledge-focused Not yet recruitingThis study explores whether the bacteria in your gut can influence how well early-stage triple-negative breast cancer responds to chemotherapy and immunotherapy. Researchers will collect stool, blood, and tumor samples from 300 women before, during, and after treatment. The goal …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC), EARLY SETTING
Sponsor: Barts & The London NHS Trust • Aim: Knowledge-focused
Last updated May 17, 2026 07:27 UTC